Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses - PubMed (original) (raw)
Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses
Guy M L Meno-Tetang et al. Drug Metab Dispos. 2006 Sep.
Abstract
FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) is a new sphingosine-1-phosphate receptor agonist being developed for multiple sclerosis and prevention of solid organ transplant rejection. A physiologically based pharmacokinetic model was developed to predict the concentration of FTY720 in various organs of the body. Single oral and intravenous doses of FTY720 were administered to male Wistar rats, with blood and tissue sampling over 360 h analyzed by liquid chromatography/tandem mass spectrometry. A well stirred model (perfusion rate-limited) described FTY720 kinetics in heart, lungs, spleen, muscle, kidneys, bone, and liver, with a permeability rate-limited model being required for brain, thymus, and lymph nodes. Tissue-to-blood partition coefficients (RT) ranged from 4.69 (muscle) to 41.4 (lungs). In lymph nodes and spleen, major sites for FTY720-induced changes in sequestration of lymphocytes, RT values were 22.9 and 34.7, respectively. Permeability-surface area products for brain, thymus, and lymph nodes were 39.3, 122, and 176 ml/min. Intrinsic hepatic clearance was 23,145 l/h/kg for the free drug in blood (f(ub) 0.000333); systemic clearance was 0.748 l/h/kg and terminal half-life was 23.4 h. The fraction orally absorbed was 71%. The model characterized well FTY720 disposition for this extensive dosing and tissue collection study in the rat. On scaling the model to dogs and humans, good agreement was found between the actual and predicted blood concentration-time profiles. More importantly, brain concentrations in dogs were well predicted from those of the rat. In absolute terms, the predictions were slightly lower than observed values, just under a 1.5-fold deviation, but the model accurately predicted the terminal elimination of FTY720 from the brain.
Similar articles
- Pharmacokinetics and cell trafficking dynamics of 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride (FTY720) in cynomolgus monkeys after single oral and intravenous doses.
Li H, Meno-Tetang GM, Chiba K, Arima N, Heining P, Jusko WJ. Li H, et al. J Pharmacol Exp Ther. 2002 May;301(2):519-26. doi: 10.1124/jpet.301.2.519. J Pharmacol Exp Ther. 2002. PMID: 11961052 - Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Foster CA, Howard LM, Schweitzer A, Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz M, Billich A. Foster CA, et al. J Pharmacol Exp Ther. 2007 Nov;323(2):469-75. doi: 10.1124/jpet.107.127183. Epub 2007 Aug 6. J Pharmacol Exp Ther. 2007. PMID: 17682127 - Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
Zollinger M, Gschwind HP, Jin Y, Sayer C, Zécri F, Hartmann S. Zollinger M, et al. Drug Metab Dispos. 2011 Feb;39(2):199-207. doi: 10.1124/dmd.110.035907. Epub 2010 Nov 2. Drug Metab Dispos. 2011. PMID: 21045200 Clinical Trial. - Overview of FTY720 clinical pharmacokinetics and pharmacology.
Kovarik JM, Schmouder RL, Slade AJ. Kovarik JM, et al. Ther Drug Monit. 2004 Dec;26(6):585-7. doi: 10.1097/00007691-200412000-00001. Ther Drug Monit. 2004. PMID: 15570180 Review. - Clinical pharmacokinetics of fingolimod.
David OJ, Kovarik JM, Schmouder RL. David OJ, et al. Clin Pharmacokinet. 2012 Jan 1;51(1):15-28. doi: 10.2165/11596550-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22149256 Review.
Cited by
- Effects of renal impairment on transporter-mediated renal reabsorption of drugs and renal drug-drug interactions: A simulation-based study.
Follman KE, Dave RA, Morris ME. Follman KE, et al. Biopharm Drug Dispos. 2018 Apr;39(4):218-231. doi: 10.1002/bdd.2128. Biopharm Drug Dispos. 2018. PMID: 29635775 Free PMC article. - Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors.
Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K. Mullershausen F, et al. Nat Chem Biol. 2009 Jun;5(6):428-34. doi: 10.1038/nchembio.173. Nat Chem Biol. 2009. PMID: 19430484 - Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
Bigaud M, Ramseier P, Tisserand S, Lang M, Urban B, Beerli C, Karlsson G. Bigaud M, et al. Neurol Ther. 2023 Aug;12(4):1187-1203. doi: 10.1007/s40120-023-00487-4. Epub 2023 May 17. Neurol Ther. 2023. PMID: 37195409 Free PMC article. - Exploring the Pharmacokinetic Mysteries of the Liver: Application of Series Compartment Models of Hepatic Elimination.
Li X, Jusko WJ. Li X, et al. Drug Metab Dispos. 2023 May;51(5):618-628. doi: 10.1124/dmd.122.001190. Epub 2023 Feb 2. Drug Metab Dispos. 2023. PMID: 36732075 Free PMC article. - Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats.
Hasegawa Y, Suzuki H, Sozen T, Rolland W, Zhang JH. Hasegawa Y, et al. Stroke. 2010 Feb;41(2):368-74. doi: 10.1161/STROKEAHA.109.568899. Epub 2009 Nov 25. Stroke. 2010. PMID: 19940275 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources